MedTrace Logo

The Effect of Semaglutide on the Intestinal Flora in Obesity

NCT07323134 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-01-07

No results posted yet for this study

Summary

For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.

Conditions

Interventions

DRUG

Semaglutide Injection

Semaglutide Injection

Sponsors & Collaborators

  • Beijing Chao Yang Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-08-01
Completion
2026-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07323134 on ClinicalTrials.gov